Highlights Scholar Rock Holding Corporation

Equities

SRRK

US80706P1030

Real-time Estimate Cboe BZX Other stock markets 11:12:58 2024-06-20 EDT			5-day change	1st Jan Change
8.3 ^USD	-2.24%		-12.41%	-56.06%

06-13	BMO Capital Raises Price Target on Scholar Rock to $31 From $29, Maintains Outperform Rating	MT
06-13	Transcript : Scholar Rock Holding Corporation Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-13-2024 09:20 AM

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Scholar Rock Reports 'Encouraging' Phase 1 Trial Results in Advanced Solid Tumors	06-03	MT
Scholar Rock to Present New Data from SRK-181 Phase 1 DRAGON Trial at the American Society of Clinical Oncology Annual Meeting	05-28	CI
Scholar Rock Starts Phase 2 Trial of Apitegromab in Obesity	05-22	MT
Scholar Rock Holding Corporation Announces Initiation of Phase 2 EMBRAZE Trial of Apitegromab in Obesity and New Preclinical Data Supporting SRK-439 in Obesity	05-22	CI
Scholar Rock Shares Fall on Wider-Than-Expected Q1 Loss	05-07	MT
Scholar Rock Holding Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07	CI
Scholar Rock Holding Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	03-19	CI
Scholar Rock Holding Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	03-19	CI
North American Morning Briefing : Stock Futures -2-	03-11	DJ
Scholar Rock Presents New Preclinical Data Demonstrating Potential Benefit of SRK-439 for Healthy Weight Loss Management	02-06	CI
Scholar Rock Says FDA Clears Application for Trial of Obesity Treatment Apitegromab	01-23	DJ
Scholar Rock Announces FDA Clearance of IND Application to Initiate Phase 2 Proof-of-Concept Trial with Apitegromab to Treat Obesity	01-23	CI
Scholar Rock Holding Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-07	CI
Scholar Rock, Inc. Presents New Data from Phase 1 Dragon Trial Showing Promising Anti-Tumor Activity in Anti-Pd-1 Resistant Metastaticcc Patients and Supporting Srk-181 Continued Tolerability	11-03	CI
Scholar Rock Announces to Present Clinical and Biomarker Data from the Phase 1 Dragon Trial At the Sitc 38Th Annual Meeting	23-10-19	CI
Scholar Rock to Advance Antimyostatin Program to Develop Novel Therapies for Cardiometabolic Disorders	23-10-11	CI
Scholar Rock Announces Completion of Enrollment for the Phase 3 SAPPHIRE Trial	23-09-19	CI
Scholar Rock Holding Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Scholar Rock Announces New Data from the Phase 2 TOPAZ Trial Extension Period Evaluating Patient Outcomes At 36 Months of Treatment with Apitegromab	23-06-30	CI
Scholar Rock Holding Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Scholar Rock Holding Corporation

Equities

SRRK

US80706P1030

Highlights

Filters